This article explores how knowledge graphs transform drug discovery by bridging disconnected biomedical data silos. By transforming “dark data” into interconnected networks of nodes and edges, knowledge graphs enable multi-hop reasoning—as seen in the rapid identification of baricitinib for COVID-19—turning isolated datasets into compounding, high-value R&D assets.
Epigenetics focuses on gene expression patterns independent of DNA sequences, notably through cytosine methylation. Understanding the methylome enhances insights into cellular functions, cancers, and aging. Quark simplifies methyl-seq data analysis, ensuring robust and reproducible results, essential for precision medicine and integrative analysis, while addressing complexity in interpretation and visualization.
Single-cell RNA sequencing (scRNA-seq) enhances understanding of cellular heterogeneity, pivotal for cancer research. However, challenges like batch effects and data complexity hinder analysis. Quark provides an end-to-end solution through horizontal integration, facilitating robust comparative analyses, accelerating insights, and enhancing workflow accessibility, crucial for effective biomarker discovery and precision medicine.
Proteomics is the comprehensive study of proteins in an organism that uncovers their dynamic roles and complexities. It aids biomarker discovery for diseases, improving drug development and treatment monitoring. Despite analytical challenges, advancements in mass spectrometry and platforms like Quark simplify data analysis, enabling researchers to identify and interpret crucial protein-related insights effectively.
GenAI is transforming drug discovery by accelerating multi-omics data analysis for biomarker identification. However, R&D organizations struggle to unify and leverage their AI-powered insights at scale. Quark’s Knowledge Graphs address this challenge by integrating multimodal data into a seamless AI-searchable graph database, ultimately accelerating research and improving clinical trial designs.
Multi-omics analysis yields 1000s of exploratory insights, impossible to navigate. GenAI leverages existing knowledge within current analytical tools to analyse massive datasets, prioritise the most relevant features and deliver key exploratory insights for drug discovery and biomarker validation.
